NCT05445934 - Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) | Biotech Hunter

Enrollment

1,188

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 31, 2023

Conditions

COVID-19

Interventions

DRUG

FB2001

FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.

DRUG

FB2001 placebo

Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.

Trial Locations (2)

Unknown

RECRUITING

Huashan Hospital Fudan University, Shanghai

RECRUITING

Beijing Ditan Hospital Capital Medical University, Beijing